Relay Therapeutics, Inc. Common Stock Earnings Dividend

Relay Therapeutics, Inc. Common Stock’s revenue fell -48.3% since last year same period to $0.35Mn in the Q2 2026. On a quarterly growth basis, Relay Therapeutics, Inc. Common Stock has generated -88.33% fall in its revenue since last 3-months.

Relay Therapeutics, Inc. Common Stock’s net profit fell -18.94% since last year same period to $-83.71Mn in the Q2 2026. On a quarterly growth basis, Relay Therapeutics, Inc. Common Stock has generated -14.21% fall in its net profits since last 3-months.

Relay Therapeutics, Inc. Common Stock’s net profit margin fell -130.07% since last year same period to -23916.29% in the Q2 2026. On a quarterly growth basis, Relay Therapeutics, Inc. Common Stock has generated -878.96% fall in its net profit margins since last 3-months.

Relay Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.4 - a 2.44% jump from last quarter’s estimates.

Relay Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.4.

Relay Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 0% since last year same period to -0.41 in the Q2 2026. This indicates that the Relay Therapeutics, Inc. Common Stock has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.